UNSPSC 51171934: Deboxamet

This classification denotes an anti-ulcer agent with the molecular formula C12H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QJH0XA6AW9, chemically known as 1h-indole-3-acetamide, n-hydroxy-5-methoxy-2-methyl- but generally known as deboxamet, which bears US NIH Compound Identifier 36660. European Medicines Agency schedules Deboxamet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06927MIG.

UNSPSC 51171934 Deboxamet is a Commodity code that encompasses drug testing and pharmaceutical procurement services for state and local government agencies. Recent solicitations show state and local buyers acquiring both specimen collection and drug testing laboratory services for criminal justice supervision programs and generic pharmaceutical products through cooperative purchasing vehicles. Collin County Community Supervision and Corrections Department is procuring offender specimen collection and drug testing services under RFP 2026-327, with an estimated contract value of $600,000 covering approximately 25,031 annual tests across two collection sites in the Dallas–Fort Worth region, requiring SAMHSA, Texas DPS, or CAP lab certification and pricing on a per-test basis for five-panel screens, six-panel screens, and ancillary testing with responses due July 23, 2026. State health and human services agencies are also active in this space — the Texas Health and Human Services Commission issued RFI No. HHS0017013 on March 27, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs operating outside traditional pharmacy benefit manager channels. The issuing-body mix spans county-level criminal justice departments and state health agencies, both of which require specialized testing certifications or manufacturing compliance standards.

Activity under this code concentrates in Texas, with Collin County's offender testing procurement and the HHS Commission's pharmaceutical initiative both representing substantial state and local demand. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) also issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson with cGMP and Drug Supply Chain Security Act compliance, 3 percent administrative fees, and performance penalties of $200 to $1,500 per violation. MMCAP's procurement spans multiple states and local government facilities, including Oregon, with contract terms commencing July 1, 2026. Recent activity under the code reflects strong demand from criminal justice and state health systems for both laboratory testing services and pharmaceutical supply — the Collin County RFP anticipates award by August 10, 2026, while MMCAP's pharmaceutical contract is structured for two-year terms with optional extensions through June 30, 2028.